Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALPL | P05186 | 1/20 | 0.38 |
| ▸ | CRHR1 | P34998 | 3/20 | 0.37 |
| ▸ | SLC6A2 | P23975 | 3/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.33 |
| ▸ | ANO1 | Q5XXA6 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6796427 | 0.90 | GAA (0.41) | ALPLCRHR1SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL6803947 | 0.90 | CRHR1 (0.38) | ALPLCRHR1CNR2 | |
| SCHEMBL6798731 | 0.89 | SLC6A2 (0.45) | CRHR1SLC6A2SLC6A4SLC6A3IRAK4 | |
| SCHEMBL6796886 | 0.79 | GAA (0.41) | CRHR1SLC6A2SLC6A4IRAK4 | |
| SCHEMBL6792226 | 0.79 | RXFP1 (0.41) | CRHR1SLC6A2SLC6A4IRAK4 | |
| SCHEMBL6803052 | 0.79 | CRHR1 (0.56) | CRHR1 | |
| SCHEMBL6798867 | 0.78 | GAA (0.50) | CRHR1SLC6A2SLC6A4SLC6A3IRAK4 | |
| SCHEMBL6794710 | 0.77 | S1PR4 (0.40) | CRHR1SLC6A2SLC6A4IRAK4 | |
| SCHEMBL6793891 | 0.77 | CRHR1 (0.40) | CRHR1 | |
| SCHEMBL6793488 | 0.76 | ALPL (0.39) | ALPLCRHR1SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6833378-B2 | Pyridines, pyrimidines, purinones, pyrrolopyrimidinones and pyrrolopyridinones; useful in the treatment disorders including CNS and stress-related disorders. | PFIZER INC | 2004-12-21 | — | — | US | claimed |
| US-20020016328-A1 | Corticotropin releasing factor antagonists | PFIZER INC. | 2002-02-07 | — | — | US | claimed |
| US-6833378-B2 | Pyridines, pyrimidines, purinones, pyrrolopyrimidinones and pyrrolopyridinones; useful in the treatment disorders including CNS and stress-related disorders. | PFIZER INC | 2004-12-21 | — | — | US | disclosed |
| EP-1263732-A1 | CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | Pfizer Products Inc. (US) | 2002-12-11 | — | — | EP | disclosed |
| US-20020016328-A1 | Corticotropin releasing factor antagonists | PFIZER INC. | 2002-02-07 | — | — | US | disclosed |
| WO-2001053263-A1 | CORTICOTROPIN RELEASING FACTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2001-07-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016328-A1 | Corticotropin releasing factor antagonists | CRH, CRHR2, CRHR1 | ALPL 4003/4885CRHR1 3/4885SLC6A2 261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.